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Abstract
Background: Tumours with high proportions of differentiated cells are considered to be of a
lower grade to those containing high proportions of undifferentiated cells. This property may be
linked to the differentiation properties of stem cell-like populations within malignancies. We aim
to identify molecular mechanism associated with the generation of tumours with differing grades
from malignant stem cell populations with different differentiation potentials. In this study we
assessed microRNA (miRNA) regulation in two populations of malignant Embryonal Carcinoma
(EC) stem cell, which differentiate (NTera2) or remain undifferentiated (2102Ep) during
tumourigenesis, and compared this to miRNA regulation in ovarian serous carcinoma (OSC)
patient samples.
Methods: miRNA expression was assessed in NTera2 and 2102Ep cells in the undifferentiated and
differentiated states and compared to that of OSC samples using miRNA qPCR.
Results: Our analysis reveals a substantial overlap between miRNA regulation in 2102Ep cells and
OSC samples in terms of miRNA biosynthesis and expression of mature miRNAs, particularly
those of the miR-17/92 family and clustering to chromosomes 14 and 19. In the undifferentiated
state 2102Ep cells expressed mature miRNAs at up to 15,000 fold increased levels despite
decreased expression of miRNA biosynthesis genes Drosha and Dicer. 2102Ep cells avoid
differentiation, which we show is associated with consistent levels of expression of miRNA
biosynthesis genes and mature miRNAs while expression of miRNAs clustering to chromosomes
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biosynthesis genes, decreased expression of mature miRNAs and prominent clustering to
chromosome 14 but not 19. This indicates that miRNA biosynthesis and levels of miRNA
expression, particularly from chromosome 14, are tightly regulated both in progenitor cells and in
tumour samples.
Conclusion: miRNA biosynthesis and expression of mature miRNAs, particularly the miR-17/92
family and those clustering to chromosomes 14 and 19, are highly regulated in both progenitor cells
and tumour samples. Strikingly, 2102Ep cells are not simply malfunctioning but respond to
differentiation specifically, a mechanism that is highly relevant to OSC samples. Our identification
and future manipulation of these miRNAs may facilitate generation of lower grade malignancies
from these high-grade cells.
Background
Stem cell-like populations from multiple different malig-
nancies can self-renew, differentiate and regenerate malig-
nant tumours [1-9]. When introduced into SCID mice, a
single so-called Cancer Stem Cell (CSC) is often sufficient
to form a tumour representative of the original malig-
nancy [8,10]. The phenotype of the resultant tumour can
vary dramatically between malignancies but almost all
CSCs generate tumours with populations of undifferenti-
ated and differentiated cells. Tumours containing high
concentrations of undifferentiated stem cells are consid-
ered to be highly malignant and differentiated tumours
less malignant. We postulate that the differentiation
capacity of the stem cell population within a malignancy
may ultimately determine tumour grade. We aim to eluci-
date why stem cells have different differentiation poten-
tials and generate tumours with different grades.
Addressing this, we have chosen the embryonal carci-
noma (EC) model, the only human stem cell model con-
taining both pluripotent and nullipotent cells [11,12].
Pluripotent NTera2 EC cells differentiate into teratocarci-
nomas, three germ layer tumours containing a small pro-
portion of undifferentiated stem cells [13]. In contrast,
nullipotent 2102Ep EC cells can avoid differentiation dur-
ing tumourigenesis, generating pure embryonal carcino-
mas, tumours consisting almost entirely of
undifferentiated stem cells [14]. Thus this model allows
comparative analysis of stem cell populations that gener-
ate highly and less malignant tumours through differing
differentiation potentials. We postulate that the mecha-
nisms facilitating tumourigenesis without differentiation
may represent an avenue for targeting.
Ovarian cancer is the 8th leading cause of cancer in women
in the US and the leading cause of death from gynaecolog-
ical malignancy in the western world [15]. Cancer of the
ovary represents about 30% of all cancers of the female
genital organs. About 205,000 cases of ovarian cancer are
diagnosed worldwide each year [16]. Strikingly, stem cell-
like populations linked to epithelial ovarian cancer (ovar-
ian serous adenocarcinoma [OSC] is the most common
histotype [17]; germ cell tumours of the ovary are rare) are
anti-apoptotic and chemoresistant, suggesting a role in
recurrent disease [18,19]. Significantly, EC is one of the
most highly aggressive forms of ovarian malignancy, and
intuitively, CSC-targeting is a potential avenue though
which anti-cancer therapeutics can be advanced.
MicroRNAs (miRNAs) are short, non-coding RNAs that
influence the transcription or translation of target mRNAs
[20,21]. Primary miRNA transcripts (pri-miRs) are proc-
essed through stem-looped pre-miRs to achieve mature
miRNAs, a process that is facilitated by the Drosha, Dicer
and eIF6 proteins. Mature miRNAs hybridize at multiple
locations along their target mRNA, including the seed
region of the 3' untranslated region (UTR) [21]. In most
cases, hybridization suspends these targets within the cell,
preventing their translation. This post-transcriptional
mechanism influences the timing at which mRNAs are
presented for translation. At least one miRNA (miR-373)
binds to a site in the promoter of its mRNA targets (E-Cad-
herin and CSDC2), acting as a positive regulator of tran-
scription [22]. Specific miRNA populations have been
described in stem cells, CSCs and malignancy in general
[20,23,24]. Additionally, miRNAs located in specific clus-
ters on chromosomes are often simultaneously synthe-
sized. Simultaneous expression of miRNAs located in
clusters along chromosomes 14 and 19 has been linked to
ovarian malignancy [25,26] while the oncogenic role of
the miR-17/92 family is well defined [27-29]. Aberrant
expression of cancer-specific 'onco-miRs' is associated
with the targeting of oncogenes and tumour suppressors
in several different malignancies [30]. Many of these miR-
NAs have been shown to be vital to cancer cells [30].
In this study, we used realtime miRNA qPCR to individu-
ally, quantitatively analyze alterations in expression of all
known miRNAs during early differentiation of NTera2
and 2102Ep EC cells. Using NTera2 cells as a model of a
functionally differentiating EC cell, we aimed to identify
miRNA mechanisms associated with the absence of differ-
entiation associated with 2102Ep cells. Our data identifiesPage 2 of 16
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genes and of mature miRNAs, particularly those associ-
ated with the miR-17/92 family and clustering to chromo-
somes 14 and 19. Interestingly, undifferentiated 2102Ep
cells express mature miRNAs at increased levels despite a
decreased level of expression of Drosha and Dicer. While
the malignancy-associated miR-17/92 cluster is promi-
nent in both undifferentiated cell types, 2102Ep-specifi-
city was associated with clustering to malignancy-
associated chromosomes 19 and 14. Expanding this anal-
ysis we have identified NTera2- and 2102Ep-specific dif-
ferentiation mechanisms that relate to miRNA
biosynthesis and expression levels of mature miRNAs.
Subsequently, we demonstrate that these mechanisms are
similarly relevant to OSC patient samples. OSCs display
up to 85% similarity with 2102Ep cells at the miRNA
level. Our data reveals that miRNA regulation in 2102Ep
EC cells is highly relevant to OSC samples.
Methods
Cell culture
Pluripotent NTera2 and nullipotent 2120Ep EC cells were
a gift from Peter Andrews, University of Sheffield, and
were maintained in the undifferentiated state in DMEM
media supplemented with 10% FCS, 5% L-Glutamine and
5% PenStrep (Lonza, Basel, Switzerland). Differentiation
was achieved by cell scraping (NTera2) or trypsinisation
(2102Ep) and replating in the above cell culture media
supplemented with 10 mM retinoic acid (RA) for 3 days.
Case selection and tumour sample preparation
The training set comprised of 6 fresh frozen serous
tumours (classified according to the FIGO system: stage
(II-IV) and grade (2-3)) and normal whole ovary. Briefly,
all tumour samples were taken from the ovary, snap fro-
zen within 1 hour of surgery and stored at -80°C. After tis-
sue processing in a cryostat at -20°C, frozen sections were
cut, mounted on slides, stained with H&E and reviewed
by a histopathologist (RJF) to confirm the original diag-
noses and the presence of >70% tumour. For validation
purposes, 40 ovarian serous carcinoma, classified as
above, were selected from archival formalin-fixed, paraf-
fin-embedded (FFPE) tissue, between the years 1991-
2006 from St. James's Hospital, Dublin. H&E slides of all
tumours were reviewed by a histopathologist (RJF) and
original diagnoses confirmed. FFPE blocks were selected
that contained over 90% tumour with contaminating
stromal tissue estimated to be no more than 10%. 10 nor-
mal whole ovaries were used for normalisation.
Isolation of RNA and TaqMan® quantitative PCR (qPCR)
Total RNA was isolated from EC cells using the RNeasy kit
(Qiagen, West Sussex, UK) and cDNA synthesised using
the cDNA Archive Kit (Applied Biosystems {AB}, Foster
City, CA), all per manufacturer's instructions. Differentia-
tion status was confirmed through TaqMan® qPCR analy-
sis (AB) using pre-designed assays. Frozen tumour
samples were placed in liquid nitrogen, ground thor-
oughly with a mortar and pestle and homogenized using
a Qiashredder column (Qiagen). miRNA was isolated
using the total RNA protocol, mirVANA™ microRNA iso-
lation kit (Ambion, Austin, TX) as per manufacturer's
instructions. Total RNA was extracted from FFPE material
using RecoverAll™ Total Nucleic Acid Extraction Kit
(Ambion Ltd., Cambridgeshire, UK) following the manu-
facturer's protocol. Quantitative miRNA realtime PCR
analysis was carried out using the TaqMan® microRNA
assay early-access panel (AB) as per manufacturer's
instructions. This panel included assays for each of the
330 human miRNAs known at the start of the study. The
protocol detects mature miRNAs using looped-primer real
time PCR involving three steps: reverse-transcription (RT),
pre-PCR amplification and real-time PCR [31]. Each RT
contained 10 ng total RNA. TaqMan® analysis was carried
out in triplicate on three biological replicate samples,
using let-7a and miR-16 as both internal and negative
controls, on the 7900 real time PCR system (AB).
Data analysis, clustering and target gene prediction
miRNA data was generated using the ΔΔCT method [32].
Data was normalised through expression of let-7a. Hierar-
chal clustering was performed on the final miRNA expres-
sion lists using the Spotfire analysis® platform (AB).
Clustering was performed using the Unweighted Pair
Group Method with Arithmetic Mean (UPGM). miRNA
clustering analysis was carried out using the Sanger Insti-
tute's miRNA registry resource miRBase [33]http://micro
rna.sanger.ac.uk/sequences/ and the DIANA miRGen [34]
miRNA resource. p-values with FDR correction were calcu-
lated using a t-test. All tests were two-tailed, and the signif-
icance level was set at P < 0.05.
Results
Undifferentiated 2102Ep EC cells display increased miRNA 
expression profiles, emphasizing high expression of 
chromosome 14 and 19 miRNAs
The expression of miRNAs was assessed both globally, via
the expression of miRNA biosynthesis genes Drosha,
Dicer and eIF6, and individually, via quantitative miRNA
qPCR analysis of a panel of 330 human miRNAs, which
generates quantitative data for each mature miRNA as an
individual assay. The relative expression of miRNA bio-
synthesis genes Dicer, Drosha and eIF6 in both undiffer-
entiated EC cell types is shown in Figure 1. While eIF6
expression was almost identical, Dicer and Drosha were
expressed at slightly and substantially lower levels in
undifferentiated 2102Ep cells compared to undifferenti-
ated NTera2 cells respectively. The same 203 miRNAsPage 3 of 16
(page number not for citation purposes)
Journal of Ovarian Research 2009, 2:19 http://www.ovarianresearch.com/content/2/1/19were expressed and 127 miRNAs undetected in both
undifferentiated cell types, indicating strong (93.5%)
qualitative similarity (Additional file 1). Undifferentiated
2102Ep cells uniquely expressed 21 additional miRNAs,
representing a mechanism that is independent of NTera2
mechanisms. 10 (NTera2) and 9 (2102Ep) of the top 10
highest expressed miRNAs have previous associations
with other malignancies (Table 1). 4 (NTera2) and 3
(2102Ep) of these miRNAs are members of the miR-17/92
family (miRs-17-5p, -19a, -19b, -106b and -25), a cluster
associated with many malignancies. The 21 2102Ep-spe-
cific miRNAs prominently cluster to regions of chromo-
somes 19 and 14 (Additional file 1).
Despite these qualitative similarities, a quantitative com-
parison identified substantial differences. Our analysis
reveals that the qualitative similarities of undifferentiated
NTera2 and 2102Ep cells are associated with the miR-17/
92 family. In contrast substantial quantitative differences
between the cells are associated with clustering to chro-
mosomes 14 and 19. 134 of the 203 miRNAs were
expressed at higher levels in 2102Ep cells compared to
NTera2 cells while 18 were downregulated (Figure 2,
Additional file 1). 17 miRNAs were particularly notable,
displaying 1,000-15,000 fold higher expression in
2102Ep cells, while 18 miRNAs showed decreased expres-
sion of up to -53 fold (Figure 3). The majority of these 17
upregulated and 18 downregulated miRNAs have previ-
ous associations with malignancy (Additional file 2).
Prominent clustering to chromosomes 14 and 19 was
apparent (Additional file 1). Additionally, 7 of these miR-
NAs are members of the miR-17/92 cluster (miRs-17-5p, -
17-3p, 18a*, -18b, -92, -106a and-363) and were up to
6,000 fold higher expressed in undifferentiated 2102Ep
cells (Tables 1, 2).
Regulation of miRNA expression by differentiated NTera2 
cells is absent in 2102Ep cells
We next treated both cell types with retinoic acid (RA) for
3 days to induce differentiation. Data is presented as the
alteration of expression in differentiated cells compared
to undifferentiated cells. This time point was chosen to
assess miRNA expression in early differentiation. Differ-
entiation status of RA-treated NTera2 cells was confirmed
by decreased expression of pluripotency markers Oct4
and Nanog and increased expression of differentiation
markers Ncam1, Eno3 and Afp (Figure 4). While eIF6
expression was unaltered, that of Drosha and Dicer was
slightly decreased in differentiated NTera2 cells (Figure 5).
113 miRNAs displayed altered expression in differenti-
ated NTera2 cells compared to undifferentiated cells (Fig-
ure 3, Additional file 3). Of these, 65 miRNAs were
upregulated and 48 downregulated (Additional file 3).
The majority of the top 10 upregulated and downregu-
lated miRNAs in differentiated NTera2 cells have previous
associations with other malignancies (Table 2). In con-
trast to undifferentiated cells, there is no overlap between
top tens in each cell type and no prominence of miR-17/
92 miRNAs is present (Additional file 3).
We next assessed the regulation of these 113 miRNAs in
2102Ep cells treated with RA. We reasoned that the
response of 2102Ep cells to RA could reveal mechanisms
associated with this cell line's ability to remain undiffer-
entiated during tumourigenesis. Unaltered expression of
pluripotency and differentiation markers confirmed nul-
Table 1: The top 10 highest expressed miRNAs in undifferentiated NTera2 and 2102Ep cells, their expression levels and associations 
with other malignancies.
miRNA Expression NTera2 (-dCt) Malignancy miRNA Expression 2102Ep (-dCt) Malignancy
Prostate [50]
miR-222 10.2 Leukaemia [51] miR-191 12.7 Leukaemia [51]
miR-19b 9.7 Lymphoma [52] miR-302a 11.8
Lymphoma [52] Prostate [50]
miR-19a 9.6 Lung [53] miR-221 11.1 Breast [59]
Oesophageal [54] Prostate [50]
miR-103 8.9 Pancreas [55] miR-222 10.3 Leukaemia [51]
Leukaemia [56] Lymphoma [52]
miR-17-5p 8.6 Colorectal [57] miR-17-3p 10.1 Colorectal [62]
Prostate [58] Oesophageal [54]
miR-135b 8.4 Breast [59] miR-103 10.0 Pancreas [55]
miR-25 7.8 Gastric [60] miR-19b 9.7 Lymphoma [52]
Ovary [61] Colorectal [57]
miR-130a 7.9 miR-92 8.8 Lymphoma [52]
Colorectal [62] Tumourigenesis
miR-30c 7.5 Ovary [61] miR-320 8.6 [63]
Gastric [60] Prostate [50]
miR-106b 7.3 Prostate [58] miR-135b 8.6 Breast [59]Page 4 of 16
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strate that high grade 2102Ep cells are associated with
unaltered expression of most miRNAs that are altered dur-
ing NTera2 differentiation. In contrast to NTera2 cells, lev-
els of eIF6, Drosha and Dicer expression were not altered
in differentiated 2102Ep cells (Figure 5). Based on their
expression in 2102Ep cells, we have placed these 113 miR-
NAs into 4 Groups (Figures 6, 7, 8 and 9 & Additional file
3). Group 1 miRNAs are expressed similarly in each cell
type. Group 2 miRNAs are altered by differentiation treat-
ment in NTera2 cells but are unaltered in 2102Ep cells.
Groups 3 and 4 miRNAs are described in the next section.
There are 16 miRNAs in Group 1 and 84 miRNAs in
Group 2. 3 and 4 Group 1 miRNAs cluster to chromo-
somes 14 and 19 respectively (Figure 6 & Additional file
3). 7 Group 2 miRNAs cluster to chromosome 14 and 16
to chromosome 19 (Figure 7 & Additional file 3). Thus,
Group 1 miRNAs represent a common mechanism while
Group2 miRNAs are NTera2-specific.
2102Ep cells respond independently to retinoic acid 
treatment
During our analysis we identified a third and fourth group
of miRNAs that represent a 2102Ep-specific response to
differentiation (Figures 8 and 9 & Additional file 3).
Group 3 miRNAs are altered in both differentiated cell
types but in an opposite fashion. Group 4 miRNAs are
Expression of miRNA biosynthesis genes and mature miR-NAs in undifferentiated NTera2 and 2102Ep EC cellsFigure 1
Expression of miRNA biosynthesis genes and mature 
miRNAs in undifferentiated NTera2 and 2102Ep EC 
cells. The relative expression levels of miRNA biosynthesis 
genes Drosha, Dicer and eIF6 in undifferentiated 2102Ep and 
NTera2 EC cells is shown. In each case, data represents 
expression in 2102Ep cells compared to NTera2. While the 
expression of eIF6 is almost identical, that of Dicer was 
downregulated slightly (4.3 fold) and of Drosha was substan-
tially lower (74.5 fold) in undifferentiated 2102Ep EC cells 
compared to undifferentiated NTera2 EC cells.
The comparative expression levels of miRNAs in undifferentiated 2102Ep cells compared to undifferentiated NTera2 cellsFigure 2
The comparative expression levels of miRNAs in undifferentiated 2102Ep cells compared to undifferentiated 
NTera2 cells. The relative expression of mature miRNAs in undifferentiated 2102Ep cells compared to Ntera2 cells is shown. 
Despite the qualitative similarities of the miRNA profiles expressed, our data indicated that the majority of miRNAs are 
expressed at higher levels in 2102Ep cells compared to NTera2.Page 5 of 16
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NTera2 cells. These groups constitute a specific 2102Ep
response to differentiation that is independent of NTera2
mechanisms. 12 Group 3 miRNAs are downregulated
while only one, miR-137, is upregulated in 2102Ep cells.
No Group 3 miRNAs cluster to regions of chromosomes
14 and 19. Group 4 contains 29 miRNAs. 17 Group 4
miRNAs are downregulated and 12 upregulated. Down-
regulated miRNAs range in expression to decreases of -633
fold. 3 miRNAs, miRs-433, -425 and -105, are only
expressed in differentiated 2102Ep cells. 5 Group 4 miR-
NAs cluster to chromosome 14 and 3 to chromosome 19
(Additional file 3). Once again, the majority of Group 3
and 4 miRNAs have previous associations with malig-
nancy (Additional file 4). While Group 2 miRNAs repre-
sent an absence of regulation in differentiated 2102Ep
cells, Groups 3 and 4 represent specific responses by dif-
ferentiated 2102Ep cells that are independent to the
response of differentiated NTera2 cells. Finally, the previ-
ously discussed group of 21 miRNAs that were expressed
in undifferentiated 2102Ep cells but not in NTera2 cells
remain unaltered upon RA treatment of 2102Ep cells.
These 21 miRNAs represent an independent miRNA
mechanism employed by 2102Ep cells in both states.
Their prominent clustering to regions of chromosomes 14
and 19, which are associated with ovarian cancer, is strik-
ing (Additional file 1).
miRNA expression in high-grade OSC samples
We have previously reported increased expression of Dicer
and eIF6 in high-grade OSC samples compared to normal
[35]. Here, the expression of 330 miRNAs in high-grade
OSC samples was assessed as above. 154 miRNAs (35 up-
and 119 downregulated) were specifically expressed in
OSCs compared to matched non-malignant ('normal')
ovarian tissue samples (Additional file 5). Our tumour
sample data shows 72% concordance with previously
published ovarian tumour data (Figure 10[26,36-40]). A
subset of miRNAs was further validated in a larger inde-
pendent cohort of OSC samples (Figure 11). This indi-
cated that our data is a good representative data set. The
top 10 up- and downregulated tumour-specific miRNAs
are illustrated in Figure 12. All but 2 of which have previ-
ous associations with malignancy (Table 3). 4 members of
the miR-17/92 family are downregulated (miRs-17-3p, -
18a*, -20a and -92) but only 1 upregulated (miR-18a) in
OSC samples. Additionally, the prominence for clustering
to chromosome 14 was maintained in OSC samples while
that to chromosome 19 was decreased (Additional file 5).
We initially compared our OSC miRNA data to that of
undifferentiated EC cells. 106 of the 203 (52%) miRNAs
commonly expressed by both undifferentiated EC cell
types were OSC-specific (Additional file 5). Of this 52%,
86 miRNAs were upregulated and 19 downregulated,
indicating a bias towards upregulation of EC-specific miR-
NAs in OSC samples. miR-17/92 family members
The comparative expression levels of 17 of the highest upregulated and 18 of the highest downregulated miRNAs in undifferen-tiated 2102Ep c lls compared to undifferen iated NTera2 cellsFigure 3
The comparative expression levels of 17 of the highest upregulated and 18 of the highest downregulated miR-
NAs in undifferentiated 2102Ep cells compared to undifferentiated NTera2 cells. The relative expression of the top 
mature miRNAs in undifferentiated 2102Ep cells compared to Ntera2 cells is shown These results demonstrate a substantial 
bias towards increased expression of mature miRNAs in 2102Ep cells. The miRNAs and levels of expression are listed in Addi-
tional file 1.Page 6 of 16
(page number not for citation purposes)
Journal of Ovarian Research 2009, 2:19 http://www.ovarianresearch.com/content/2/1/19expressed in OSC samples are similarly expressed in EC
cells. 10 of the 21 (48%) 2102Ep-specific miRNAs were
similarly OSC-specific (Additional file 5). The promi-
nence for clustering to chromosome 14 was maintained in
OSC samples while that to chromosome 19 is lost.
Relevance of OSC-specific miRNAs to EC cells
OSC miRNA data was next compared to differentiated EC
miRNA data. Hierarchal clustering indicated that OSC
samples clustered with 2102Ep cells while NTera2 cells
were more divergent (Figure 13). This is in concordance
with the highly aggressive phenotype of 2102Ep EC cells
but may also be related to lineage-specificity. Approxi-
mately 85% of OSC-specific miRNAs were expressed in
2102Ep cells (Additional file 5). The majority of tumour-
specific miRNAs (whether up- or downregulated in
tumours) were consistently expressed in 2102Ep cells. The
next largest overlap was observed for tumour-specific
miRNAs that were downregulated in 2102Ep cells. Com-
paratively few tumour-specific miRNAs were upregulated
in 2102Ep cells. This indicates that tumour-specific miR-
NAs are tightly regulated in 2102Ep cells. We next asked
whether the top 10 up- and downregulated OSC-specific
miRNAs play a role in 2102Ep cells. All but 2 (miRs-202*
and -216) top downregulated tumour-specific miRNAs
were detected in 2102Ep cells. All of the top upregulated
tumour-specific miRNAs were detected in 2102Ep cells.
We subsequently assessed the relevance of Group 1 2, 3
and 4 miRNAs to OSC samples. Approximately half of
Group 1 and 2 miRNAs were found to be OSC-specific,
the majority of which were downregulated in OSC sam-
ples (Additional file 3). Prominent clustering to chromo-
some 14 is maintained in OSC samples but is
substantially decreased for chromosome 19. 62% of
Group 3 miRNAs and 38% of Group 4 miRNAs were OSC-
specific, again showing a bias towards downregulation of
miRNAs (Additional file 3). Clustering to chromosomes
Table 2: The top 10 highest expressed miRNAs in differentiated NTera2 and 2102Ep cells, their expression levels and associations with 
other malignancies.
miRNA Relative Expression Malignancy miRNA Relative Expression Malignancy
Downregulated NTera2 Downregulated 2102Ep
Tumourigenesis [63]
miR-507 -100,000 miR-518c* -634.0
miR-142-5p -100,000 Lung [64] miR-153 -30.9
Lung [77]
miR-520b -100,000 let-7g -10.1 Colon [78]
miR-522 -100,000 miR-504 -9.9
miR-122a -100,000 miR-362 -8.1
Lymphoma [52]
miR-515-5p -100,000 miR-17-3p -6.2 Colorectal [62]
miR-182* -100,000 Prostate [65] miR-511 -3.4 Liver [47]
miR-199a* -100,000 Lung [66] miR-193b -3.2 Endometrial [72]
Mesothelioma [67]
miR-7 -100,000 Lung & Breast [68] miR-455 -2.8
miR-206 -100,000 Breast [69] miR-431 -2.7
Upregulated NTera2 Upregulated 2102Ep
Kaposi Sarcoma [70] Medullablastoma [79]
miR-140 6.1 Breast [30] miR-199b 2.6
Breast [59] Lymphoma [80]
miR-191* 6.7 Leukaemia [51] miR-363 2.6
miR-188 8.3 miR-129 3.0 Gastric [81]
Endometrial [71] Tongue [78]
miR-99b 11.1 miR-184 3.8 Neural [82]
miR-509 18.3 miR-519d 3.8
Tongue [72] Breast [75]
miR-219 21.9 miR-10a 119.2 Leukaemia [83]
Lung [73]
miR-99a 22.5 Ovary [35] miR-433 100000
Ovary [61] Glioblastoma [84]
miR-335 26.0 Myeloma [74] miR-425 100000
Breast [75] Multiple [85]
miR-10a 100000 Leukaemia [51] miR-105 100000
Prostate [76] Glioblastoma [86]
let-7c 100000 Lung [52] miR-137 100000 Melanoma [87]Page 7 of 16
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in OSC samples. This identifies a substantial group of
miRNAs that are regulated in both EC cells and OSC sam-
ples. Regulation of Group 3 miRNAs was particularly rel-
evant to OSC samples.
Discussion
Compromising the ability of CSCs to remain in the undif-
ferentiated state is a potential avenue for anti-cancer ther-
apies. Before this can be achieved, we must identify
mechanisms involved. 2102Ep cells are the stem cell pop-
ulation of ECs, malignant tumours that can arise in the
ovary [11]. In vivo, these cells avoid differentiation to pro-
duce highly-aggressive, poorly-differentiated tumours
[11]. In this study we report that miRNA regulation is
associated with this phenotype. In undifferentiated cells,
this involves decreased expression of miRNA biosynthesis
genes, increased expression of mature miRNAs and
expression of miRNAs clustering along chromosomes 14
and 19. When treated with RA, 2102Ep cells avoid differ-
entiation and continue to proliferate. This is associated
with consistent levels of expression of miRNA biosynthe-
sis genes and mature miRNAs while expression of miR-
NAs clustering to chromosomes 14 and 19 is
deemphasised. OSC samples displayed decreased expres-
sion of miRNA biosynthesis genes, decreased expression
of mature miRNAs and prominent clustering to chromo-
some 14 but not 19. This indicates that miRNA biosynthe-
sis and levels of miRNA expression, particularly from
chromosome 14, are tightly regulated both in progenitor
cells and in tumour samples.
Differentiation status and miRNA biosynthesis gene expres-sion in differe tiated NTera2 and 2102Ep cellFigu  4
Differentiation status and miRNA biosynthesis gene 
expression in differentiated NTera2 and 2102Ep cells. 
The expression of markers of pluripotency (Oct4 and 
Nanog) and of endoderm (Afp), ectoderm (Ncam1) and mes-
oderm (Eno3) differentiation is shown. In each case, data rep-
resents changes in expression in the differentiate state 
compared to undifferentiated state. In NTera2 cells, differen-
tiation status is confirmed by decreases in expression of 
Oct4 and Nanog and increases in expression of Afp, Ncam1 
and Eno3. 2102Ep cells alter expression of these genes less 
than two-fold, confirming nullipotency.
The expression levels of the miRNA biosynthesis genes Dro-sha, Dicer and eIF6 in different ated cells compared to undif-fer ntiated cellsFigure 5
The expression levels of the miRNA biosynthesis 
genes Drosha, Dicer and eIF6 in differentiated cells 
compared to undifferentiated cells. Expression of Dro-
sha decreases 65 fold while that of Dicer decreases 2.6 fold 
and of eIF6 decreased less than 2 fold upon differentiation of 
NTera2 cells. In contrast, the level of differential expression 
of each gene is within 1.0 fold in both undifferentiated and 
differentiated 2102Ep cells. Maintained expression of miRNA 
biosynthesis genes, therefore, is associated with the 2102Ep 
nullipotent phenotype.
Comparison of the expression levels of miRNAs altered in different ated NT ra2 and 2102Ep cells: Group 1 miRNAsFigure 6
Comparison of the expression levels of miRNAs 
altered in differentiated NTera2 and 2102Ep cells: 
Group 1 miRNAs. miRNAs were grouped according to 
their expression patterns upon differentiation of NTera2 and 
2102Ep cells. 15 Group 1 miRNAs are similarly altered in 
both cell types. We propose that Group 1 miRNAs likely act 
upstream of any lesion in the 2102Ep differentiation mecha-
nism. miRNAs in each group are listed in Additional file 3.Page 8 of 16
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Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 2 miRNAsFigure 7
Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 2 
miRNAs. miRNAs were grouped according to their expression patterns upon differentiation of NTera2 and 2102Ep cells. 85 
Group 2 miRNAs are altered in NTera2 cells but unaltered in 2102Ep cells. We propose that Group 2 miRNAs likely act 
downstream of any lesion in the 2102Ep differentiation mechanism. miRNAs in each group are listed in Additional file 3.
Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 3 miRNAsFigure 8
Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 3 
miRNAs. miRNAs were grouped according to their expression patterns upon differentiation of NTera2 and 2102Ep cells. 13 
Groups 3 miRNAs are altered in an opposite fashion in each cell line. Group 3 miRNAs represent a 2102Ep-specific response 
to differentiation that is independent of NTera2 mechanisms. miRNAs in each group are listed in Additional file 3.
Journal of Ovarian Research 2009, 2:19 http://www.ovarianresearch.com/content/2/1/19Mechanistically, our data indicates that undifferentiated
2102Ep EC cells can express more miRNAs at higher levels
of expression than NTera2 cells despite their decreased
expression of miRNA biosynthesis genes. We have previ-
ously described the association of decreased eIF6 expres-
sion with high-grade OSC samples from patients with
reduced disease-free survival [35]. In concordance with
this, decreased Dicer and Drosha expression is linked to
advanced stage ovarian cancer and increased expression to
increased patient survival [41]. Interestingly, eIF6 expres-
sion was unaltered in EC cells. This indicates the complex-
ity of miRNA biosynthesis regulatory mechanisms in EC
stem cells and tumours. This mechanism is clearly linked
to higher grade malignancy and its elucidation will be the
subject of ongoing analysis. The levels of expression of
miRNAs were higher in undifferentiated 2102Ep cells
than NTera2 cells. 2102Ep cells express 21 miRNAs in
both states that are not expressed by NTera2 cells. Simi-
larly, OSC samples showed biased upregulation of miR-
NAs compared to non-malignant samples. Thus levels of
mature miRNA expression are tightly controlled both in
progenitor cells and developed tumours. It is widely
reported that specifically regulated miRNA groups com-
monly occur in clusters on specific chromosomes. Promi-
nent clustering to three particular sites was observed in
this study: the miR-17/92 cluster and chromosomes 14
and 19, which have been linked with numerous malig-
nancies. miR-17/92 family clusters are associated with
regulation of proliferation, angiogenesis and apoptosis in
malignancy [27-29]. These miRNAs were highly expressed
by both undifferentiated cell types and were not promi-
nently 2102Ep specific. Previous associations of chromo-
some 19 with germ cell tumours and of chromosome 14
with ovarian cancer are particularly striking [26,42]. miR-
NAs with 2102Ep specificity prominently clustered to
these chromosomes while Group 1 miRNAs did not. miR-
Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 4 miRNAs.Figure 9
Comparison of the expression levels of miRNAs altered in differentiated NTera2 and 2102Ep cells: Group 4 
miRNAs. 29 Group 4 miRNAs are altered in RA-treated 2102Ep cells but unaltered in differentiated Ntera2 cells. Group 4 
miRNAs represent a 2102Ep-specific response to differentiation that is independent of Ntera2 mechanisms. miRNAs in each 
group are listed in Additional file 3.Page 10 of 16
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notype and will be assessed by ongoing analysis.
2102Ep cells avoid differentiation through a mechanism
that involves maintained expression of pluripotency mas-
ter genes Oct4 and Nanog [11]. We have identified
miRNA regulation mechanisms associated with this phe-
notype. Group 1 miRNAs behave similarly in each EC cell
type and are thus likely to act upsteam of the 2102Ep dif-
ferentiation lesion. Group 2 miRNAs are altered upon dif-
ferentiation of NTera2 cells but not in 2102Ep cells,
suggesting that their role lies downstream of the 2102Ep
differentiation lesion. It is possible that Group 1 miRNAs
are involved with initiation of tumourigenesis from EC
cells. For example, miR-10a targets HoxA1, a long estab-
Comparison of miRNA expression in OSC patient samplesFigure 10
Comparison of miRNA expression in OSC patient 
samples. The venn diagram shows the number of differen-
tially expressed miRNAs identified in the current study and 
the number of miRNAs identified in six previous studies 
[26,36-40]. These overlap substantially.
Validation of OSC patient sample miRNA dataFigure 11
Validation of OSC patient sample miRNA data. Vali-
dation of training set: Log10 RQ values for miR-429, mir-141 
and let-7f in both the pilot study (RQp) and the larger inde-
pendent FFPE cohort (RQv). There was modest correlation 
between both sets of results (r = 0.50).
Top 10 miRNAs up- and downregulated in OSC patient samplesFigure 12
Top 10 miRNAs up- and downregulated in OSC patient samples. Barchart of the mean logarithmic fold change (RQ) 
of the top ten up and downregulated miRNAs in OSC samples relative to normal ovary.Page 11 of 16
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mately half of these miRNAs were OSC-specific,
indicating that both groups are relevant to tumour biol-
ogy. This may be reflective of the heterogeneous nature of
tumour samples, which contain a spectrum of differenti-
ating cell types. Our data indicates that unaltered expres-
sion of Group 2 miRNAs is associated with the ability of
2102Ep cells to remain in the undifferentiated state in the
presence of a differentiation signal. Maintenance of these
miRNAs may protect these EC cells from differentiation
signals in vivo. This is supported by their reported vali-
dated targets. For example, differentiation regulators are
targeted by miRs-199a (Bmp2) and -206 (MyoD) [44,45].
The future characterisation and manipulation of this
lesion may facilitate generation of lower grade tumours
from 2102Ep cells.
The substantial overlap between miRNAs expressed by EC
cells and in OSC samples exists despite their different phe-
notypes. EC is of germ cell origin whilst OSC is of epithe-
lial origin. However, morphologically, EC is composed of
primitive epithelial cells, which may explain the similari-
ties reported here. It may also be related to tissue-specific
expression or reflect a temporal relationship in terms of
degree of dedifferentiation Regulation of miRNA biosyn-
thesis and mature miRNA expression in these diverse sam-
ples indicates the importance of these mechanisms to
ovarian malignancy generally. More than 80% of tumour-
specific miRNAs were expressed in 2102Ep cells. This
clearly indicates that miRNA regulation in 2102Ep cells is
highly relevant to tumour samples, more relevant than
miRNA regulation in tumour samples is to 2102Ep cells.
Many of these miRNAs have reported associations with
malignancy. Stem cells represent a small proportion of a
well-differentiated tumour. In contrast, 2102Ep cells gen-
erate a malignant tumour in vivo that is almost completely
EC cells [11,14], while melanoma contains a high propor-
tion of stem cells [46]. Thus it is not surprising that highly
aggressive 2102Ep cells are more relevant to tumour sam-
ples than NTera2 cells.
In this study we have identified two 2102Ep-specific
mechanisms. A group of 21 miRNAs are constantly
expressed, half of which are OSC-specific. The functional
significance of this overlap is suggested by their validated
targets. For example, miR-224 targets apoptosis inhibitor
5 (Api5) while miR-503 suppresses cyclinD1 [47,48].
2102Ep cells respond to RA treatment via a second spe-
cific mechanism that is independent of NTera2 mecha-
nisms and has not been previously demonstrated. Group
3 miRNAs are alternatively regulated in each differenti-
ated cell type. This represents a 2102Ep mechanism that,
in response to differentiation, acts in the exact opposite
fashion to NTera2 cells. Approximately 62% of Group 3
miRNAs were OSC-specific, the largest overlap observed
between EC cells and OSC samples. Group 3 miRNAs rep-
resent a key target group for future analysis. It is tempting
to postulate that this mechanism may facilitate counterac-
tion of differentiation to some extent, a possibility that
will be assessed through ongoing analysis. miR-137 is an
interesting example as it is expressed in only differentiated
2102Ep cells and in undifferentiated NTera2 cells and is
associated with stemness and malignancy [49]. miR-137
is downregulated in OSC samples, indicating complex
regulation. The identification of a fourth group of miR-
NAs is potentially highly relevant to our understanding of
tumourigenesis from 2102Ep cells. Group 4 miRNAs are
altered upon RA treatment of 2102Ep cells. In contrast,
Group 4 miRNAs are not altered in NTera2 cells. This indi-
cates that 2102Ep cells can regulate a specific miRNA
response to this differentiation signal. Group 4 miRNAs
displayed the lowest overlap with OSC samples. This sug-
gests that Group 4 miRNAs are highly relevant to 2102Ep
cells. It is possible that Group 4 miRNAs may act against
differentiation to contribute to the high grade phenotype,
a possibility that is being actively assessed.
Table 3: The top 10 highest expressed miRNAs in OSC patient 
samples compared to normal ovary, their expression levels and 
associations with other malignancies.
miRNA Relative Expression Malignancy
Downregulated
miR-383 -1000
miR-216 -250 Pancreas [88,89]
miR-508 -142.9
Leukaemia [55]
miR-204 -71.5 Pancreas [88]
miR-509 -67.1
Gastric [89]
miR-497 -47.6 Breast [90]
miR-153 -33.3
miR-202* -19.6 Leukaemia [91]
miR-188 -17.2
Liver [92]
miR-195 -16.9 Bladder [93]
Upregulated
miR-429 2082 Ovary [37,94]
Metastasis [95]
miR-200c 600 Pancreas [96]
Metastasis [95]
miR-141 533 Gastric [97]
Lung [98]
miR-183 510 Colorectal [54]
miR-187 237 Thyroid [99]
miR-200a 145 Ovary [36,94]
miR-182 113 Prostate [83]
Metastasis [95]
miR-200b 103 Pancreas [96]
miR-200a* 67 Ovary [38,94]
Oesophageal [100]
miR-373 59 Leukaemia [51]Page 12 of 16
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The highly malignant phenotype of 2102Ep EC cells
employs a three pronged mechanism of miRNA regula-
tion involving miRNA biosynthesis, levels of mature
miRNA expression and alternative expression of miRNAs
in response to differentiation. This miRNA regulation is
associated with the ability of 2102Ep cells to avoid differ-
entiation to generate high-grade tumours and that is rele-
vant to tumour samples. These miRNAs are either
similarly or alternatively expressed during tumourigene-
sis. As the precise mechanisms of miRNA targeting are still
being elucidated, it is possible that miRNAs expressed in
2102Ep cells may play similar or diverse roles in OSCs.
Due to their association with high-grade progenitor cells
and tumours, Group 3 and 4 miRNAs are of particular rel-
evance to future analysis.
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